Julia Letlow - Integrity Index View Julia Letlow's political integrity grade, campaign financing, and conflicts of interest.

Rep. Julia Letlow (R-LA) disclosed 7 trades:
Traded: Feb 12 | Disclosed: Mar 12

Bought: $META ($1K-$15K), $EXR ($1K-$15K), $REGN ($1K-$15K)
Sold: $TTWO ($1K-$15K), $ICLR ($1K-$15K), $AVGO ($1K-$15K), $T ($1K-$15K)

https://integrityindex.us/candidate/julia-letlow

#REGN #e533cb25-3014-48c8-b4d7-6088eefac69d #investing #Health #Care

Origin | Interest | Match

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients Regeneron (NASDAQ: REGN) reported positive Phase 3 topline results from Hansoh's 48-week trial of olatorepatide in Chinese adults with obesity or overweight. The randomized, double-blind trial (N=604) met co-primary endpoints with up to 19% mean weight loss at week 48 and up to 97% achieving ≥5% weight loss.The program showed favorable gastrointestinal tolerability (nausea 10%, vomiting

#REGN Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

www.stocktitan.net/news/REGN/olatorepatide-...

#REGN REGENERON
Q4 EPS USD 7.86
Q4 REVENUE USD 3,884 MILLION VS ESTIMATE USD 3,800 MILLION
Q4 ADJUSTED EPS USD 11.44 VS ESTIMATE USD 10.6
OUTLOOK FY CAPEX USD 1,100-1,300 MILLION

#ZTS #REGN #4db793c9-fb53-4206-b5cb-4661e3784529 #investing #Health #Care

Origin | Interest | Match

BREAKING NEWS: ( NASDAQ: #REGN ) 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow

#REGN Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

www.stocktitan.net/news/REGN/regeneron-and-...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) Regeneron (NASDAQ: REGN) and Sanofi announced on November 25, 2025 that the European Commission approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12+ with inadequate response to H1 antihistamines who are naïve to anti-IgE therapy.Approval is based on the LIBERTY-CUPID Phase 3 program: two pivotal trials (Study A and Study C, combined n=284) and an additional safety study (Study B, n=108) showing significant reductions in itch and hives at 24 weeks, higher rates of well-controlled disease and complete response, and a safety profile consistent with prior Dupixent indications. Approximately 270,000 EU patients may be eligible.

#REGN Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

www.stocktitan.net/news/REGN/dupixent-dupil...

#REGN has surged since our Value algorithm consistently ranked it a top value name in September, October, and November.
#ValueInvesting

Vinteren er på vej i Gaza. Kraftig regn presser udsatte palæstinensere Flere palæstinensere har endnu en gang måttet finde et nyt sted at opholde sig, efter at voldsomme regnskyl har oversvømmet flere teltlejre i den sydlige del af Gaza-striben.

17/11 2025

#Vinteren er på vej i #Gaza. #Kraftig #regn presser udsatte palæstinensere

www.dr.dk/nyheder/udla...

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy,

#REGN Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

www.stocktitan.net/news/REGN/regeneron-high...

Regeneron Reports Third Quarter 2025 Financial and Operating Results Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD ® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA ® U.S. net sales decreased 28% to $1.11 billion GAAP

#REGN Regeneron Reports Third Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/REGN/regeneron-repo...

Idag bjuder Borås på … Boråsväder.
#regn #borås #ingakonstigheter

#DXCM #REGN #e3487d43-7bbb-45ff-81b2-0a996ffd6220 #investing

Origin | Interest | Match

Har ju gått ned från 10+ koppar kaffe per arbetsdag till bara 4, har gått bra hittills i höst, men det är nu utmaningen börjar. #mörker #regn #höst

#MRNA #REGN #38fee4b0-56c0-453c-ab20-ebe9d1a88012 #investing

Origin | Interest | Match

#REGN call butterfly for March. Buy 700, sell 750, buy 800. Still fairly far OTM as max profit is just below 750.

Diskusfinalen dröjer #regn #vm

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD Regeneron Pharmaceuticals (NASDAQ: REGN) has presented complete 26-week results from its Phase 2 COURAGE trial at EASD, investigating combinations of semaglutide with trevogrumab for obesity treatment. The study demonstrated that adding trevogrumab could prevent approximately 50% of lean mass loss associated with semaglutide-induced weight loss.Key findings show that while 33% of semaglutide-induced weight loss was from lean mass loss, the combination therapy achieved better body composition outcomes. The triplet combination (including garetosmab) showed the most significant results with only 7.4% lean mass loss and 92.6% fat mass loss. All treatment groups demonstrated numerical improvements in metabolic and lipid parameters.The combinations were generally well-tolerated, though the triplet therapy group experienced higher discontinuation rates and two deaths occurred, which haven't been causally linked to the treatment.

#REGN Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

www.stocktitan.net/news/REGN/results-from-p...

Dagens outfit inkluderar sydväst, hink och gummiraka! #regn

After rain the sun came ......... and to my surprise a whole rainbow! Can't remember when I last saw one of those ........... 😎
Efter regn kommer sol ... overrasket over at se en hel regnbue, længe siden set en ...... 😎
#rain #rainbow #sun #autumn #denmark
#regn #sol #regnbue #efterår #danmark

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies Regeneron Pharmaceuticals (NASDAQ: REGN) announced positive Phase 3 trial results for its first-in-class allergen-blocking antibodies targeting cat and birch allergies. The trials demonstrated significant symptom reduction compared to placebo.In the cat allergy trial, a single dose of REGN1908/REGN1909 reduced itch by 52%, conjunctival redness by 39%, and skin prick reactivity by 44%. For birch allergy, REGN5713/REGN5715 showed similar efficacy with 51% itch reduction, 46% conjunctival redness reduction, and 44% decrease in skin prick reactivity.Both treatments showed rapid onset within 8 days and durability lasting over 3 months. The company plans additional Phase 3 development, with cat allergy trials starting in H1 2026 and birch allergy trials by year-end.

#REGN Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

www.stocktitan.net/news/REGN/regeneron-adva...

#ISRG #REGN #b0aa8d79-01b9-43a7-a54e-86291b502b73 #investing

Origin | Interest | Match

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis Regeneron (NASDAQ: REGN) announced positive Phase 3 NIMBLE trial results for cemdisiran monotherapy in treating generalized myasthenia gravis (gMG). The trial met its primary and key secondary endpoints, with cemdisiran showing a 2.3-point placebo-adjusted improvement in MG-ADL total score.Cemdisiran, administered subcutaneously every three months, demonstrated 74% inhibition of complement activity. The trial also tested a cemdisiran-pozelimab combination, achieving 99% inhibition, though cemdisiran monotherapy showed numerically better results. Key efficacy metrics include 76.6% of patients achieving ≥3-point MG-ADL reduction and 48.4% achieving ≥5-point QMG reduction.The safety profile was favorable, with no meningococcal infections and no treatment discontinuations due to adverse events in the cemdisiran arm. Regeneron plans U.S. regulatory submission in Q1 2026.

#REGN Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

www.stocktitan.net/news/REGN/regeneron-anno...

FDA Extends Review Timeline: Regeneron's EYLEA HD Faces Q4 2025 Decision for Expanded Uses FDA extends review of EYLEA HD's prefilled syringe and expanded indications to Q4 2025. Delay follows Catalent facility inspection. Current vial administration remains available for approved uses.

#REGN EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

www.stocktitan.net/news/REGN/eylea-hd-aflib...

#Regn på vej. #Aarhus

#REGN #SNY #VKTX #21dc398f-2cb7-4e9a-9f9e-51a687afbc73 #investing

Origin | Interest | Match

Regeneron Reports Second Quarter 2025 Financial and Operating Results Regeneron (NASDAQ:REGN) reported strong Q2 2025 financial results with total revenues increasing 4% to $3.68 billion. Key highlights include Dupixent global sales growth of 22% to $4.34 billion and EYLEA HD U.S. sales growth of 29% to $393 million, though total EYLEA franchise sales decreased 25% to $1.15 billion.The quarter saw significant regulatory achievements, including FDA approvals for Lynozyfic in multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria. The company reported GAAP EPS of $12.81 (up 3%) and non-GAAP EPS of $12.89 (up 12%).Notable pipeline progress includes positive obesity trial results, manufacturing challenges affecting EYLEA HD approvals, and a strategic in-licensing deal for a late-stage GLP-1/GIP receptor agonist. The company returned over $2.3 billion to shareholders through share repurchases and dividends.

#REGN Regeneron Reports Second Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/REGN/regeneron-repo...

Stop regnen fra at sive ind i dit hjem 🚫

Det regner og regner og regner... Og det ser ikke ud til at stoppe lige foreløbigt ☔

Her er vores gode råd til at sikre dit hus mod oversvømmelse 👇
#danskeberedskaber #beredskabet #oversvømmelse #regn